EU Approves Rheumatoid Arthritis Drug Of Japan’s Chugai
This article was originally published in PharmAsia News
Executive Summary
The European Union has approved a rheumatoid-arthritis drug developed by Japan's Chugai Pharmaceutical, now controlled by Roche. The drug is RoActemra (tocilizumab), whose U.S. approval as Actemra is being delayed for 18 months because the FDA wants a new animal test and additional information. Analysts estimate annual sales of at least $2 billion. Roche has the rights to market Actemra outside Japan. Roche said the drug will be sold with another drug for patients who fail to respond to other treatments. (Click here for more - a subscription may be required